RNXT RenovoRx, Inc. Insider Trading

CFO Mark Voll buys 25,000 shares of RNXT at $0.79; stock down 44.1% from 52-week high

Mark Voll, Chief Financial Officer, purchased 25,000 shares at $0.79 on 2026-05-19, increasing his holdings by 21.3% to 142,380 shares. The current price of $0.81 remains 44.1% below the 52-week high of $1.45, with the stock down 19.4% over the past 30 days and 13.9% over 90 days. His prior purchase at this ticker on 2026-03-20 returned -19.0% over 90 days, and his cross-ticker track record shows 1 prior buy with an average 90-day return of -19.0% and a 0.00% win rate. The company is unprofitable with net income of $-3.5M against quarterly revenue of $563.0K, though annual revenue growth reached 2511.6% year-over-year.

CFO Mark Voll acquires 97,200 shares of RNXT; cluster buy with 2 others in 14 days

CFO Mark Voll purchased 97,200 shares on 2026-03-20, establishing a first position at the company. This buy occurs as part of a cluster pattern, with 2 other insiders also purchasing within the past 14 days. The company generated $266,000.00 in revenue in its latest quarter but reported a net loss of $-2.9M and carries a market cap of $39.6M. The stock is currently trading at $1.08, down 23.9% from its 52-week high but up 18.3% over 30 days and up 20.6% over 90 days. Simultaneous buying by multiple insiders at an unprofitable company warrants examination of whether the recent price recovery reflects changing fundamentals or represents informed conviction about turnaround prospects.

Director Marton Laurence buys 9,720 shares of RNXT; cluster buy pattern detected with 2 other insiders buying within 14 days

Marton Laurence (Director) purchased 9,720 shares of RenovoRx on 2026-03-20, bringing his holdings from 0 to 9,720 shares. This transaction is part of a cluster pattern—2 other insiders also bought within the past 14 days—suggesting potential coordinated activity among leadership. Notably, his prior two purchases at RNXT (on 2025-04-08 and 2024-01-26) both showed positive 90-day returns of 22.6% and 55.7% respectively, establishing a pattern of well-timed entry points at this specific ticker. Against this backdrop, the current stock price of $1.08 is 23.9% below the 52-week high, creating a circumstance where multiple insiders are initiating or adding positions in an unprofitable company with minimal recent revenue ($266.0K in the latest quarter and net loss of $-2.9M). The convergence of insider buying activity, favorable historical timing outcomes at this ticker, and depressed valuation relative to recent highs warrants investor attention to the underlying business developments driving this apparent confidence.

CEO Bagai Shaun buys 24,300 shares of RenovoRx (RNXT) on 2026-03-20; CLUSTER pattern: 3 insiders buying within 14 days.

Bagai Shaun, CEO, acquired 24,300 shares on 2026-03-20, raising his holdings from 289,057 shares to 313,357 shares (+8.4%). This purchase is part of a cluster pattern in which 2 other insiders also bought within the past 14 days, suggesting coordinated conviction at this price level. RenovoRx remains unprofitable (net income of $-2.9M in the latest full fiscal year) with minimal quarterly revenue of $266.0K, making this a high-risk biotech story. Bagai's prior trades at RNXT show mixed timing outcomes: 3 of 5 prior buys were well-timed at the 90-day mark, including a +53.9% 90-day return on an April 2025 purchase and +40.1% and +31.9% returns on consecutive August 2025 buys, though recent December 2025 purchases returned only +13.2% and +19.7% respectively over 30 days. The stock has risen 18.3% over the past 30 days and 20.6% over 90 days but remains -23.9% from its 52-week high of $1.42, creating a technical backdrop where the insider's persistence merits attention given the company's losses.

CMO Agah Ramtin buys 10,000 shares of RNXT at $1.00; fourth buy in 18 days amid -33.8% 52-week decline and $-2.9M net loss.

Agah Ramtin, Chief Medical Officer of RenovoRx, purchased 10,000 shares at $1.00 on 2026-01-21, bringing his holdings to 798,460 shares. This is his fourth open-market purchase within an 18-day window (2025-12-05 through 2026-01-21), a pattern of sequential accumulation at RNXT. The stock is trading at $1.02, down 33.8% from its 52-week high of $1.54 and off 13.6% over the past 90 days despite a +12.1% bounce in the last 30 days. Critically, RenovoRx reported only $266,000 in latest quarterly revenue against a $-2.9M net loss, with negative full-year earnings and a $37.4M market cap—a micro-cap biotech in financial distress. While Ramtin's cross-ticker track record shows an 83.33% 90-day win rate on buys (avg +40.8% return), his five same-ticker purchases at RNXT show mixed near-term results (three measurable 30-day outcomes: +21.2%, -13.0%, +11.9%), with no 90-day outcomes yet available to assess timing. The repeated, discrete purchases over less than three weeks warrant investor attention to whether they reflect conviction in a distressed asset or something else.

CMO Ramtin bought 9,795 shares of RNXT at $0.86; stock down 22.1% over 90 days while company posts $-2.9M net loss.

Agah Ramtin, Chief Medical Officer, purchased 9,795 shares of RenovoRx at $0.86 on 2025-12-31, increasing his holdings to 788,460 shares (+1.3% vs prior). This transaction occurs in the context of RenovoRx's weak fundamentals: the company reported $-2.9M net income in its most recent period and remains unprofitable over its full fiscal year, with minimal revenue of $266.0K. The stock has declined 22.1% over the prior 90 days and is currently 38.3% below its 52-week high of $1.54. While Ramtin's cross-ticker track record shows strong results (11 prior buys averaging +40.8% 90-day returns with 83.33% win rate), his same-ticker history at RNXT shows mixed outcomes: of five measurable prior trades at this ticker, only one achieved a 90-day result (none were well-timed by the 90-day mark). This latest purchase follows three buys within the prior 10 days (2025-12-30, 2025-12-16, 2025-12-05), suggesting sustained accumulation despite ongoing operational losses and negative price momentum.

CMO Agah Ramtin buys 205 shares of RNXT at $0.83; stock down 45.4% from 52-week high, company posting $-2.9M net loss.

Agah Ramtin, Chief Medical Officer, purchased 205 shares at $0.83 on 2025-12-30, adding modestly to his 778.7K-share position. This marks his fifth open-market purchase of RNXT in approximately 40 days (prior buys on 2025-12-31, 2025-12-16, 2025-12-05, 2025-11-24, and 2025-11-21), suggesting sustained accumulation despite deteriorating price action. The stock has declined 45.4% from its 52-week high and 7.1% over the past 30 days, while the company reported $266.0K in quarterly revenue against a $-2.9M net loss, indicating ongoing unprofitability. His cross-ticker buying record shows a 83.33% 90-day win rate with an average 90-day return of +40.8%; however, at RNXT specifically, the timing of his earlier buys remains unmeasurable at the 90-day horizon, offering no evidence of accuracy in this particular equity.

CEO Bagai Shaun buys 5,000 shares of RNXT at $0.90; stock down 41.6% from 52-week high but up 13.1% in 30 days.

Bagai Shaun, Chief Executive Officer of RenovoRx Inc., purchased 5,000 shares at $0.90 on 2025-12-18, increasing his holdings to 340,040 shares. The purchase occurs in a context of significant volatility: the stock is down 41.6% from its 52-week high of $1.54 but has rebounded 13.1% over the prior 30 days. Critically, the company remains unprofitable (full-year net income was negative, with the latest quarter showing net income of $-2.9M against revenue of $266.0K), presenting a fundamental risk environment. Across his prior trades at RNXT, Bagai has shown mixed timing: 2 of 4 measurable prior buys were well-timed at the 90-day mark (30-day returns of +22.0% and +27.7% extended to +53.9% and +56.6% at 90 days), but the two most recent completed transactions (2025-08-25 and 2025-08-22) showed deteriorating 90-day outcomes (-12.5% and -18.0% respectively despite strong 30-day returns). This latest purchase warrants investor attention to whether it represents opportunistic accumulation at a depressed point in a volatile cycle or conviction in turnaround prospects at a company with substantial operational headwinds.

CEO Shaun Bagai buys 5,000 RNXT shares at $0.85; stock down -39.6% from 52-week high but up +27.0% in 30 days.

Shaun Bagai, Chief Executive Officer of RenovoRx, purchased 5,000 shares at $0.85 on 2025-12-17, increasing his holdings to 335,040 shares. This transaction occurs as the stock trades $0.93, within its 52-week range of $0.73–$1.54, down -39.6% from its peak but up +27.0% over the past 30 days—suggesting near-term momentum into the purchase. Examining Bagai's prior trading at RNXT: of his 4 measurable same-ticker buys, 2 achieved positive 90-day returns (+53.9% and +56.6%), while 2 resulted in negative 90-day returns (-12.5% and -18.0%), indicating mixed timing outcomes at this specific ticker. The company remains unprofitable with net income of $-2.9M on quarterly revenue of $266.0K and a market cap of $34.1M, which underscores that this buy occurs in the context of a pre-revenue-stage biotech facing significant financial headwinds. The purchase is modest in absolute terms ($4.3K) relative to his existing position, yet the pattern of his repeated buying (5 prior trades at RNXT) alongside ongoing losses warrants attention to whether the CEO's conviction in the science outweighs current financial metrics.

CMO Agah Ramtin buys 12,000 shares of RenovoRx at $0.85, accumulating 778.5K shares amid unprofitable fundamentals and recent repeat purchases.

Agah Ramtin, RenovoRx's Chief Medical Officer, purchased 12,000 shares at $0.85 on 2025-12-16, adding to recent buying activity at this ticker with purchases also made on 2025-12-05, 2025-11-24, and 2025-11-21. His cross-ticker track record shows 9 prior open-market buys with an average 90-day return of +40.8% and an 83.33% win rate; however, at RNXT specifically, timing outcomes are mixed—his 2025-04-15 buy returned +55.6% at 90 days, but his 2025-06-05 buy returned -10.7% at 90 days. The current stock price of $0.87 is -43.5% from its 52-week high of $1.54 and +8.2% over 30 days, but the company reported revenue of $266.0K in the latest quarter with net income of -$2.9M and a market cap of $31.9M, indicating continued losses and a micro-cap profile. The repeated purchases within a compressed timeframe coupled with unresolved fundamental weakness warrant monitoring of whether these accumulations reflect insider conviction or reflect volatility-driven execution in a distressed valuation environment.